How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

865 results for

Endocrine Manifestations of HIV

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

141. Realising the potential of stratified medicine

on the findings of the 2007 symposium, which confirmed the advantages of stratified medicine. Stratification represents a more targeted approach to therapy, with the potential for greater efficacy of treatments and minimisation of their side effects. For example, stratification means that the 2–9% of patients who test positive for a particular genetic biomarker of hypersensitivity to Ziagen (abacavir, an HIv nucleoside reverse transcriptase inhibitor) are no longer prescribed this medication. Decreases both (...) of disease, recent years have seen the number of stratified medicines expand from only a few, such as Herceptin (trastuzumab, a breast cancer treatment only suitable for those who overproduce the HER2 protein), Gleevec (imanitib, a specific inhibitor of a mutant kinase in chronic myeloid leukemia) and Ziagen (abacavir, an HIv inhibitor potentially fatal to carriers of a specific genetic variant), to a wider range of medicines, for instance addressing melanoma (Zelboraf, vermurafenib, which targets BRAF

2013 Academy of Medical Sciences

142. The Initial Reproductive Health Visit

care services and the federal and state laws that affect confidentiality. Timing and Scope of the Initial Visit The initial visit for screening and the provision of reproductive preventive health care services and guidance should take place between the ages of 13 years and 15 years ( , ). This may be a patient’s first visit to an obstetrician–gynecologist. From a developmental standpoint, patients of this age may manifest characteristics of early, middle, or late adolescence. An attempt (...) is within normal limits ( ). Clinicians should ask detailed questions about the patient’s menstrual cycle to help uncover abnormalities that may be easily managed (eg, dysmenorrhea and nonsteroidal antiinflammatory drugs as an effective treatment) or may be linked to a more serious underlying concern (eg, bleeding, müllerian, and endocrine disorders) (8). Adolescents with disabilities and developmental delays may especially benefit from an initial reproductive health visit with an obstetrician

2014 American College of Obstetricians and Gynecologists

143. Clinical Practice Guideline: The Diagnosis, Management, and Prevention of Bronchiolitis

not apply to children with immunodeficiencies, including those with HIV infection or recipients of solid organ or hematopoietic stem cell transplants. Children with underlying respiratory illnesses, such as recurrent wheezing, chronic neonatal lung disease (also known as bronchopulmonary dysplasia), neuromuscular disease, or cystic fibrosis and those with hemodynamically significant congenital heart disease are excluded from the sections on management unless otherwise noted but are included (...) in children younger than 2 years, including a viral upper respiratory tract prodrome followed by increased respiratory effort and wheezing. Clinical signs and symptoms of bronchiolitis consist of rhinorrhea, cough, tachypnea, wheezing, rales, and increased respiratory effort manifested as grunting, nasal flaring, and intercostal and/or subcostal retractions. The course of bronchiolitis is variable and dynamic, ranging from transient events, such as apnea, to progressive respiratory distress from lower

2014 American Academy of Pediatrics

144. Royal Flying Doctor Service Western Operations Clinical manual part 1.Clinical guidelines

(Paediatric) 5 1.5 The Deteriorating Patient 7 2 CARDIOVASCULAR 1 2.1 Acute Coronary Syndromes 1 2.2 Acute Pulmonary Oedema 6 2.3 Cardiac Arrhythmias 8 3 ENDOCRINE 1 3.1 Diabetic Ketoacidosis 1 3.2 Hypoglycaemia 3 3.3 Hypocalcaemia 5 4 GASTROINTESTINAL 1 4.1 Acute Pancreatitis 1 4.2 Haematemesis and Melaena 3 4.3 Intestinal Obstruction 5 5 GENITOURINARY 1 5.1 Acute / Chronic Renal Failure 1 6 INFECTIOUS DISEASES 1 6.1 Bacterial Meningitis 1 6.2 Meningococcal Infection 3 6.3 Tuberculosis 5 6.4 Meliodosis 6

2014 Clinical Practice Guidelines Portal

145. Management of Stable Coronary Artery Disease

; (iii) those who report symptoms for the ?rst time and are judged to already be in a chronic stable condition (for instance because history-taking reveals that similar symptoms were already present for several months). Hence, SCAD de?nes the different evolutionary phases of CAD, excluding the situations in, which coronary artery thrombosis dominates clinical presentation (acute coronary syn- dromes). However, patients who have a ?rst or recurrent manifestation of angina but can be categorized (...) . Naturalhistoryandprognosis In many patients, early manifestations of CAD are endothelial dys- function and microvascular disease. Both are associated with an increased risk of complications from CAD. 20– 22 Contemporary data regarding prognosis can be derived from clin- ical trials of anti-anginal and preventive therapy and/or revasculariza- tion, although these data are biased by the selected nature of the populations studied. From these, estimates for annual mortality rates range from 1.2–2.4% per annum, 23– 28

2013 European Society of Cardiology

146. Hepatic Encephalopathy

in the treatment of complications of cirrho- sis (renal failure, infections, and variceal bleeding [VB]), studies performed more than 30 years ago have generally not been considered for these guidelines. Introduction Hepatic encephalopathy (HE) is a frequent compli- cation and one of the most debilitating manifestations of liver disease, severely affecting the lives of patients and their caregivers. Furthermore, cognitive impair- ment associated with cirrhosis results in utilization of more health care (...) dysfunction caused by liver insuf?ciency and/or PSS; it manifests as a wide spectrum of neurological or psychiatric abnormalities ranging from subclinical alterations to coma. This de?nition, in line with previous versions, 10,11 is based on the concept that encephalopathies are “diffuse disturbances of brain function” 5 and that the adjective “hepatic” implies a causal connection to liver insuf?ciency and/or perihepatic vascular shunting. 6 Epidemiology The incidence and prevalence of HE are related

2014 American Association for the Study of Liver Diseases

148. Clinical practice guideline for care in pregnancy and puerperium

is the purpose of universal screening for group B streptococcus in pregnant women and at what stage of pregnancy should it be done? 20. What is the purpose of universal screening for human immunodeficiency virus (HIV) in pregnant women and at what stage of pregnancy should it be done? 21. What is the purpose of universal screening for symptomatic bacteraemia in pregnant women and at what stage of pregnancy should it be done? 22. What is the purpose of universal screening for anaemia and at what stage (...) and the puerperium period, but does not provide information on situations that require extra care such as: Previous pathology • Heart disease, including high blood pressure • Kidney disease • Diabetes mellitus and other endocrine disorders • Chronic respiratory disease: severe asthma • Hematologic diseases, including thalassemia, sickle cell anaemia and thrombophilia • Autoimmune diseases with systemic involvement: antiphospholipid antibody syndrome • Epilepsy and other neurological diseases • Psychiatric

2014 GuiaSalud

149. Dietary Phytoestrogens as Risk Factors for Systemic Lupus Erythematosus

unknown even though genetic and environmental factors have already been identified. Estrogens, on one side, have been shown to negatively influence the incidence and severity of the disease while testosterone and progesterone on the other side are thought to be protective. Endocrine disruptors can potentially influence the occurrence and severity of the disease. Among these disruptors, soy isoflavones which are ubiquitous in modern processed food are known to be estrogenic and anti-androgenic (...) : Premenopausal women over 18, having given informed consent, and being covered by social insurance. Exclusion Criteria: Group Systemic Lupus Erythematosus and group autoimmune diseases Human Immunodeficiency virus (HIV), hepatitis C virus (HCV) or hepatitis C virus (HBV) sero-positivity; pregnant or lactating women; menopausal women; patient in remission of quiescent phase of her pathology; Healthy controls : HIV, HCV or HBV sero-positivity; pregnant or lactating women; menopausal women. Contacts

2018 Clinical Trials

150. Williams Syndrome Strength, Hormones, Activity & Adiposity, DNA Programming, Eating Study

Posted : November 29, 2018 Last Update Posted : November 29, 2018 See Sponsor: Massachusetts General Hospital Collaborators: Lipedema Foundation Williams Syndrome Association Information provided by (Responsible Party): Barbara R. Pober, Massachusetts General Hospital Study Details Study Description Go to Brief Summary: Williams syndrome (WS) is a rare microdeletion genetic disorder that has a broad phenotype including many endocrine and metabolic abnormalities. Dr. Pober and colleagues at MGH have (...) or abnormal fat distribution due to a known secondary cause (except WS) such as Cushing syndrome, HIV-infection, etc. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03758651 Contacts Layout table for location contacts Contact: Barbara Pober, MD 617-726

2018 Clinical Trials

151. TAK-659 and Paclitaxel in Treating Patients With Advanced Solid Tumors

Terminology Criteria for Adverse Events) version 5.0 [ Time Frame: Up to 4 years ] Adverse events (clinical manifestations and laboratory tests) and serious adverse events will be assessed by clinical symptoms and laboratory values, evaluation of vital signs, and performance of physical exam with a special attention to treatment-related fatigue, gastrointestinal symptoms, cardiovascular events, myelosuppression, and neurotoxicity. Incidence and grade of adverse events assessed by NCI CTCAE version 5.0 (...) [ Time Frame: Up to 4 years ] Will assess incidence and grade of adverse events (clinical manifestations and laboratory tests) with particular attention to >= grade 2 adverse events over time by dose. Maximum tolerated dose [ Time Frame: Up to 28 days ] Defined according to the 3+3 design. Deaths during the study will be documented. Secondary Outcome Measures : Dose-limiting toxicity [ Time Frame: Up to 28 days ] Categorization of response based on Response Evaluation Criteria in Solid Tumors 1.1

2018 Clinical Trials

152. A Study to Evaluate Different Intervals Between Dosing and Feeding on the Pharmacokinetics

Criteria: Age ≥ 18 years old The subject's body weight was ≥ 50.0 kg, BMI was between 19 and 26 kg/m2 Signed informed consent. Exclusion Criteria: Any clinically serious disease that has or is currently suffering from circulatory, endocrine, nervous, digestive, respiratory, hematological, immunological, psychiatric, and metabolic abnormalities, or any other disease that can interfere with the test results Having deep vein thrombosis or other thrombotic diseases. Having thrombocytopenia, mitral valve (...) prolapse, obvious heart murmur, or murmur. Extended QT interval during the screening period (calculated in Bazett's method, males >450 msec) Hepatitis B surface antigen, hepatitis C antibody, syphilis antibody, HIV antibody positive. Those who have a history of allergies to drugs , food or test drugs or similar drugs; Those who have undergone surgery within 4 weeks prior to the trial or plan to perform surgery during the study Those who took any drug within 14 days before the test (including Chinese

2018 Clinical Trials

153. Transarterial Chemoembolization in Combination With Nivolumab Performed for Intermediate Stage Hepatocellular Carcinoma

metastases with one organ system manifestations, e.g. lymphnodal, pulmonary, ossary metastases. For lymphnodal metastases Maximum three metastases, maximum 2 cm in the longest diameter, and for all other metastases only solitary metastases, maximum 2 cm in the longest diameter, are allowed. Patients on a liver transplantation list or with advanced liver disease as defined below: Encephalopathy; Untreatable ascites. Any contraindications for hepatic embolization procedures: Known hepatofugal blood flow (...) . Prior systemic anti-cancer therapy OR endocrine- OR immunotherapy Prior treatment with TACE RFA and resection administered less then 4 weeks prior to study treatment start. Radiotherapy administered less then 4 weeks prior to study treatment start. Major surgery within 4 weeks of starting the study treatment OR subjects who have not recovered from effects of major surgery. Patients with second primary cancer, except adequately treated basal skin cancer or carcinoma in-situ of the cervix

2018 Clinical Trials

154. Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer

be considered for the exploratory arm, Arm 4. Serious concomitant systemic disorders incompatible with the study (at the discretion of the investigator), such as significant cardiac or pulmonary morbidity e.g. congestive heart failure, symptomatic coronary artery disease and cardiac arrhythmias not well controlled with medication) or myocardial infarction within the last 12 months, ongoing infection as manifested by fever. Pregnant or lactating women. Women of childbearing potential with either a positive (...) test for hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus ribonucleic acid (HCV antibody) indicating acute or chronic infection Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS). Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would

2018 Clinical Trials

155. Novel Approach for the Prevention of Hypoglycemia Associated Autonomic Failure (HAAF)

, barbiturates, benzodiazepines, cocaine, methadone, opiates, PCP Currently taking beta-blockers or medications that affect counterregulatory response to hypoglycemia Urinalysis: clinically significant abnormalities Clinically significant electrolyte abnormalities Smoking >7 cigarettes/day Heavy alcohol use History of chronic conditions (eg, chronic liver disease, cardiovascular disease, bleeding disorders, cancer, HIV/AIDS, seizures, systemic rheumatologic conditions) Surgeries involving endocrine glands (...) Unconsciousness Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases Autoimmune Diseases Immune System Diseases Primary Dysautonomias Autonomic Nervous System Diseases Nervous System Diseases Consciousness Disorders Neurobehavioral Manifestations Neurologic Manifestations Signs and Symptoms Naloxone Diazoxide Narcotic Antagonists Physiological Effects of Drugs Sensory System Agents Peripheral Nervous System Agents Antihypertensive Agents Vasodilator Agents

2018 Clinical Trials

156. Dose-escalating Phase I Trial With GEM333 in Patients With Acute Myeloid Leukemia

. Male patients must also practice a highly effective method of birth control. Able to give written informed consent Weight ≥ 45 kg Exclusion Criteria: Acute promyelocytic leukemia (t15;17) Manifestation of AML in central nervous system Leukocytosis > 10 Gpt/L Cardiac disease: i.e. heart failure NYHA III or IV; unstable coronary artery disease (Myocardial Infarction more than 6 months prior to study entry is permitted); serious cardiac ventricular arrhythmias requiring anti-arrhythmic therapy (...) malignancy requiring active therapy but adjuvant endocrine therapy is allowed Checkpoint inhibitors und CD33 targeting agents within 8 weeks prior to start of trial medication Autoimmune diseases requiring systemic steroids or other systemic immunosuppressants Treatment with any investigational drug substance or experimental therapy within 4 weeks prior to start of trial medication or 5 half lives of the substance prior to start of trial medication Pregnant or breastfeeding women Psychologic disorders

2018 Clinical Trials

157. Mass Balance Study With MT-7117

and the Investigator, the medication will not interfere with the objectives of the study or compromise the subject's safety (Note: The use of acetaminophen [2 g/day for up to 3 consecutive days] will be permitted from Screening and during the study). 4. Clinically significant (in the opinion of the Investigator) endocrine, thyroid, hepatic (including Gilbert's syndrome), respiratory, gastrointestinal or renal disease, diabetes mellitus (type I and II), coronary heart disease, hypertension, or significant history (...) at each visit. 7. Has a positive hepatitis B surface antigen, hepatitis B core antibody, hepatitis C virus antibody, or human immunodeficiency virus type 1 (HIV-1) and type 2 (HIV-2) result at Screening. 8. Clinically significant abnormal 12-lead ECG findings, including subjects with corrected QT interval using Fridericia's formula (QTcF) of >450 ms, or presence of atrial fibrillation or other significant arrhythmia at Screening or Day -1, confirmed by repeat assessment. 9. Any surgical or medical

2018 Clinical Trials

159. Inpatient, Dose-Ranging Study of Staccato Alprazolam in Epilepsy With Predictable Seizure Pattern

to progress in the next 3 months Use of strong CYP 3A4 inhibitors; including azole antifungal agents (e.g., etoconazole, itraconazole), nefazodone, fluvoxamine, cimetidine, HIV protease inhibitors (e.g., ritonavir) Has severe chronic cardio-respiratory disease History of HIV-positivity. Pregnant or breast-feeding. Clinically significant renal or hepatic insufficiency (hepatic transaminases >2 times the upper limit of normal (ULN) or creatinine ≥ 1.5 x ULN). History of acute narrow angle glaucoma (...) ) measured while seated at screening or baseline. Significant hepatic, renal, gastroenterologic, cardiovascular (including ischemic heart disease and congestive heart failure), endocrine, neurologic or hematologic disease. Subjects who, in the opinion of the Investigator, should not participate in the study for any reason, including if there is a question about the stability or capability of the subject to comply with the trial requirements. Contacts and Locations Go to Information from the National

2018 Clinical Trials

160. Phase 2b Study of KBP-5074 in Subjects With Uncontrolled Hypertension and Advanced Chronic Kidney Disease

heart failure manifested by signs and symptoms that may require intravenous diuretic therapy (New York Heart Association Class III to IV) within 3 months prior to Screening, or presence of hemodynamically significant valve diseases and/or other hemodynamically significant obstructive lesions of left ventricular outflow tract; Major cardiac, cerebral, and/or carotid artery diseases, including, but not limited to, acute coronary syndrome, myocardial infarction, stroke, and/or transient ischemic attack (...) at Screening or the end of the run-in period, defined as aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >3 × the upper limit of normal (ULN) or total bilirubin >2 × ULN; o Note: Patients with total bilirubin >2 × ULN and history of Gilbert's syndrome may be included. Positive blood screen for human immunodeficiency virus (HIV), hepatitis B surface antigen (HbsAg), or hepatitis C virus (HCV) antibody; History of prescription drug abuse, illicit drug use, or alcohol abuse according

2018 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>